Norditropin Daily denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Issues a "Not FDA-Approved" Denial for Norditropin

This denial type appears when UHC determines that Norditropin (somatropin) is being prescribed for a use that it believes falls outside the drug's FDA-approved labeling — commonly called an "off-label" use — or when the clinical documentation submitted does not clearly identify a labeled indication. It can also occur when authorization paperwork omits the specific diagnosis code or ICD-10 that maps to an FDA-approved indication. This denial is frequently correctable.

## Why This Denial Is Appealable

Norditropin has multiple FDA-approved indications. If the prescription is for a recognized labeled indication — and the chart clearly documents the qualifying diagnosis — the denial rests on a documentation or coding error, not a clinical one. Even for off-label uses, many plans are required by law or their own policy to cover uses supported by recognized compendia (such as the AHFS Drug Information compendium or NCCN Drug and Biologics Compendium), and some state laws further expand coverage obligations. Review your plan documents and applicable state law carefully.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plan) or applicable state insurance law. Include documentation that establishes which FDA-approved indication applies — or, if off-label, which recognized compendia support the use.
• External review: Under ACA §2719, a final adverse benefit determination is subject to binding independent external review. The general external-review window is four months from the denial notice date. The IRO will assess whether the denial was consistent with the terms of the plan and applicable medical evidence.
• Expedited review: Available when a delay poses an imminent threat to health.

## Concrete Appeal Steps and Timeline

1. Pull the denial letter and identify exactly which indication or use UHC is contesting. 2. Compare the stated diagnosis against the FDA-approved indications listed in the current Norditropin prescribing information (the FDA label is available at DailyMed, fda.gov). 3. If the use is on-label, ensure the correct diagnosis code appears on the authorization and claim, and have your prescriber confirm in writing. 4. If the use is off-label, research whether a recognized drug compendium supports it and whether your plan or state law requires coverage of compendium-supported uses. 5. File the written internal appeal with the prescriber letter and label excerpt. 6. Escalate to external review if needed.

## Documentation to Gather

• FDA label excerpt: A printed copy of the "Indications and Usage" section of the Norditropin prescribing information, with your specific indication highlighted.
• Diagnosis documentation: Lab results, growth records, genetic reports, or specialist notes confirming the qualifying diagnosis with appropriate ICD-10 coding.
• Prescriber letter: A signed statement from the prescribing physician naming the specific FDA-approved indication, citing the diagnostic evidence, and stating that the prescribed use is consistent with the label.
• Compendium citation (if off-label): If the use is not FDA-labeled, include the specific compendium entry supporting the use and the evidence basis.

## Criteria-Mapping Structure

Build your appeal around a direct match between the FDA label and the chart:

| FDA-Approved Indication (from label) | Chart Evidence Confirming This Indication | |---|---| | [Copy indication language verbatim from the Norditropin prescribing information] | [Diagnosis code, lab result, specialist note — exact date and source] |

A tight, well-cited appeal package demonstrating an on-label use is among the most straightforward denials to overturn.